The following conclusions can be drawn from the existing literature. 7) In untreated diabetes mellitus, the serum concentration of low-density lipoprotein choles-
terol (LDL-chol) is within normal limits. Hyperlipidemia, if present, involves an increase in serum triglyceride (TG) and very-low-density lipoprotein TG (VLDL-TG) and cholesterol (VLDL-chol) concentrations. High-density lipoprotein cholesterol (HDL-chol) levels may also be decreased, particularly in non-insulin-dependent diabetes mellitus (NIDDM). 2) Diabetes mellitus and familial hyperlipoproteinemias are not genetically coinherited. Their frequent coexistence could result from their independent association with other metabolic disorders such as obesity.
3) The mechanism of the lipoprotein disorder in diabetes affects the metabolism of plasma VLDL, LDL, and HDL. To a major extent, the disorder relates to the metabolic milieu of the diabetic syndrome, although the mechanism(s) of increased apolipoprotein B (apoB) production and decreased HDLchol concentration observed in some diabetic individuals remains unknown. 4) Treatment of hyperglycemia is associated with improvement in plasma VLDL and LDL concentrations and is often accompanied by some improvement in plasma HDL levels, particularly when associated conditions, such as obesity, are dealt with concurrently. 5) Epidemiological surveys, dietary intervention trials, and studies in experimental animals provide strong evidence that dietary fat, particularly saturated fat, and cholesterol restriction could exert favorable influences on plasma lipid and lipoprotein levels as well as on cardiovascular risk. Increasing the carbohydrate content and some types of fiber may also be beneficial. The potential benefit of specific fatty acid supplements (omega-3 fatty acids) remains to be clarified.
Based on these conclusions, the following recommendations are made. Because of the high risk of cardiovascular disease (CVD) among diabetic subjects, the known association between abnormalities in plasma DIABETES CARE, VOL. 1 1 , N O . 2, FEBRUARY 1988 lipids and lipoprotein concentrations and increased CVD risk, and the established favorable effects of a fatmodified diet on plasma lipids and lipoprotein concentrations, as a minimal requirement, diabetic subjects should be prescribed a diet in which total fat is restricted to 30% of total calories, saturated fat to <10%, polyunsaturated fat to 6-8%, with the remaining calories as monosaturated fat. Cholesterol content should not exceed 300 mg/day [comparable to that of the American Heart Association (AHA) phase I diet recommended for the American public at large].
Because normolipemia may not be achieved with optimal antidiabetic therapy in some subjects, a more restrictive fat-modified diet that limits total fat to 25% of calories and cholesterol to 200-250 mg/day or fat to 20% of calories and cholesterol to 100-150 mg/day (comparable to the AHA phase II or phase III, respectively) with or without additional hypolipidemic agents should be prescribed to individuals who continue to exhibit persistently elevated LDL-chol despite maximum efforts to optimize their antidiabetic therapy. Individuals who continue to exhibit an increase in VLDL-TG and VLDL-chol concentrations are not likely to benefit from the stricter fat-modified diets. Because their lipoprotein abnormality involves an increase in apoB production, a pattern similar to that of the highly atherogenic familial hyperlipoproteinemic disorders such as familial-combined hyperlipidemia and the hyperapobetalipoproteinemia syndrome, their management includes hypolipidemic agents appropriate for the treatment of these hyperlipoproteinemic disorders.
In the unusual circumstance of massive hypertriglyceridemia (plasma TG 1000-2000 mg/dl, the chylomicronemia syndrome) in which the danger of acute pancreatitis is high, dietary fat intake should be restricted initially to 10-20% of total calories; primary treatment includes appropriate antidiabetic therapy, management of accompanying secondary causes of hyperlipidemia, and possibly a fibric acid derivative.
These recommendations should be further modified to accommodate the nutritional management of accompanying disorders such as obesity, hypertension, and renal disease. Weight reduction is an important goal in NIDDM. Correction of obesity usually results in improved glycemic control and beneficial changes in plasma lipoprotein concentrations with reductions of plasma VLDL and LDL and increases of HDL. In addition, appropriate medical management of other risk factors for coronary heart disease, such as cigarette smoking and hypertension, should be emphasized.
IS SERUM LIPID OR LIPOPROTEIN CONCENTRATION IN DIABETES DIFFERENT FROM THAT OF NONDIABETIC POPULATION?
In the major clinical types of diabetes, serum lipid concentrations are altered, and in some individuals plasma lipid levels, particularly TG, may be extremely elevated.
In insulin-dependent diabetes mellitus (IDDM) with ketoacidosis, plasma TG levels are often markedly elevated, whereas cholesterol concentrations are only modestly increased (1). In IDDM subjects undergoing short-term withdrawal of insulin therapy, a small but consistent rise in fasting plasma TG concentration occurred (2). Furthermore, in young NIDDM patients studied prospectively, increasing levels of hemoglobin A, or fasting blood glucose are associated with increases in total plasma TG and cholesterol concentrations (3,4). In some individuals, an extreme situation in which ketoacidosis associated with massive hypertriglyceridemia may also occur (2,5).
Serum lipid concentrations in NIDDM have been studied exhaustively. A number of large epidemiologic investigations have contributed to our appreciation of the frequent association between NIDDM and hyperlipidemia (6-9). Both serum cholesterol and TG concentrations have been reported to be higher in diabetic subjects compared with the normal population. TG and cholesterol concentrations are shifted toward higher values in diabetic subjects with vascular complications compared with those without. In the Framingham study, diabetic subjects were found to have higher cholesterol than the general population, but elevated serum TG was a better predictor of vascular disease than serum cholesterol (7). Most studies have shown that body weight is positively correlated with plasma TG concentrations.
Despite the frequent assertion of a significant relationship between diabetes mellitus and abnormalities in plasma lipid levels, the exact prevalence of hyperlipidemia in diabetes varies greatly. Indeed, any conclusion concerning the prevalence and interaction of diabetes and hyperlipidemia must be qualified with the understanding that: 7) the diagnosis of diabetes and hyperlipidemia is usually imprecise; 2) both diabetes and hyperlipidemia overlap with other conditions such as obesity; 3) the type of patient in a diabetic population under study can be strongly influenced by the specific interest of the investigator (e.g., probably more patients followed in lipid clinics or by cardiologists are hyperlipidemic subjects than those derived from diabetic clinics); 4) common conditions that affect lipoprotein metabolism, e.g., renal disease and use of diuretic agents and (3-adrenergic blocking drugs, which are particularly prevalent in the diabetic patient, may influence the study's conclusions; and 5) customary use in the past of a carbohydrate-restricted diet with a reciprocal increase in fat could also affect this relationship.
To obviate these biases, a population-based study recently evaluated the prevalence of hyperlipidemia in diabetes in an American suburban population (10). Total plasma cholesterol was not elevated. However, hypertriglyceridemia was observed in association with diabetes. The increase in plasma TG was independent of age and relative body weight. Plasma lipoprotein levels measured in a random sample of NIDDM individuals in this population revealed that VLDL-chol levels are increased and HDL-chol levels are decreased. No abnor-mality in LDL concentration was observed (11). In the much larger World Health Organization multinational study of vascular disease in diabetes, serum TG and cholesterol levels were measured in 5 of the 14 national samples of patients (12). Several risk factors for coronary heart disease, e.g., hypertriglyceridemia, hypertension, and obesity, are noted to cluster in diabetic patients (12,13). Ischemic heart disease is also strongly associated with plasma TC levels.
The predominant lipoprotein abnormality in diabetes is an increase in VLDL concentration. A decrease in HDL concentration is often observed in NIDDM. Although elevated LDL has been noted, most studies continue to report LDL as the density fraction 1.006-1.063, which also includes the intermediate density lipoprotein (IDL) composed largely of remnants of VLDL metabolism. When studies separate the intermediate fraction, most of the elevation in total LDL is due to an increase in IDL (14,15).
receptor gene is located on chromosome 19. The apolipoprotein E and CM (apoE and apoCII) genes are also present on this chromosome, but no studies have been undertaken to assess the relationship of these genetic loci to diabetes and its association with hyperlipidemia and coronary heart disease. Another important area of future research concerns the relationship between diabetes mellitus and the regulation of apoB gene expression, because some NIDDM patients demonstrate an increase in apoB production, a metabolic pattern similar to that observed in familial-combined hyperlipidemia, in the hyperapobetalipoproteinemia syndrome, and in some normolipemic individuals with coronary heart disease. These disorders are associated with a high risk for coronary heart disease, even in the normolipemic state, such as might occur in NIDDM. With the information available to us at the present time, it does not appear that diabetes mellitus and genetic hyperlipemias are coinherited as the result of a common gene aberration.
ARE FAMILIAL OR GENETIC FORMS OF HYPERLIPIDEMIA COINHERITED AND/OR OVERREPRESENTED IN DIABETIC SUBJECTS?
Familial hypercholesterolemia in its monogenic or polygenic forms does not appear to be more frequent in diabetic subjects than in the general population (16). Undoubtedly, there is some overlap between diabetes and the familial forms of hypertriglyceridemia (familial hypertriglyceridemia and familial-combined hyperlipidemia), because these two disorders are commonly associated with obesity, insulin resistance, and hyperinsulinemia. It is important to define the nature of this overlap because familial-combined hyperlipidemia exerts a high risk for coronary heart disease. Initial studies have suggested that the familial hypertriglyceridemias and overt diabetes are inherited together (16,17). More recent reports, on the other hand, demonstrate that the two disorders segregate or are inherited separately, and that their simultaneous occurrence is only by chance (18). A major difficulty in interpreting these studies is the unavailability of a biochemical and/or a molecular marker that is readily applicable to the identification of these lipoprotein disorders and, consequently, there is a need to screen a large number of surviving first-degree relatives. Thus, the prevalence of familial-combined hyperlipidemia in both the diabetic and the nondiabetic population is likely to be underestimated.
Recent studies suggest that the human insulin gene is present on the short arm of chromosome 11 (19). The 5' end of this gene is a highly variable region characterized by insertions of different lengths. The gene for the apoproteins Al and CHI (apoAl and apoCIII), important regulators of HDL and VLDL metabolism, is also present on chromosome 11. Polymorphism in this region is suggested in NIDDM patients, particularly in those with hypertriglyceridemia (20-22). However, this is not supported by other reports (23,24). The insulin
WHAT IS THE MECHANISM OF LIPID/LIPOPROTEIN DISORDER IN DIABETES, AND TO WHAT EXTENT COULD IT BE RELATED TO DIABETIC METABOLIC MILIEU?

EXOGENOUS LIPIDS
Although animal studies suggest that insulin-deficient diabetes is associated with enhanced intestinal cholesterol transport (25,26), human studies do not agree (27-29). Also, there is no evidence that chylomicron synthesis is increased in diabetic subjects. Patients with normal serum TG concentrations have essentially normal clearance of chylomicrons, whereas those with high fasting TG have delayed chylomicron clearance, which returns to normal after insulin therapy. The abnormality in chylomicron metabolism in diabetes thus relates to the decline in lipoprotein lipase (LPL) characteristic of insulin deficiency in IDDM; this defect is overcome by insulin administration. However, studies have not assessed the metabolic fate of chylomicron remnants in diabetes, i.e., whether these remnants are removed in the normal way via hepatic uptake and catabolism or removed by extrahepatic tissues.
Occasionally, massive hypertriglyceridemia with chylomicronemia occurs in diabetic patients (chylomicronemia syndrome; 30). Their lipoprotein phenotype can be either type I or severe type V. The latter is more frequent in diabetes. This is usually manifest with abdominal pain, impaired memory, paresthesia, hepatomegaly, and eruptive xanthoma, which clear as plasma TG levels are lowered. Although it was originally thought that this extreme hypertriglyceridemia was completely due to severe insulin deficiency (diabetic lipemia), in most instances, an additional familial form of hypertriglyceridemia is also present. Most patients with this condition not only have defective lipolysis due to a deficiency and/or dysfunction of LPL but also enhanced synthesis of VLDL, which contributes to the very high VLDL levels.
ENDOGENOUS LIPIDS
In diabetic subjects, endogenous cholesterol and bile acid synthesis are increased independently from obesity. Bile is commonly supersaturated with cholesterol (27,29). Interestingly, synthesis of both cholesterol and bile acid remains elevated during insulin therapy, presumably due to imperfect control of hyperglycemia, although the presence of a fundamental defect in cholesterol synthesis unrelated to insulin deficiency needs to be evaluated.
Generally, the disorder of lipoprotein metabolism in diabetes affects plasma VLDL, LDL, and HDL, but the mechanisms involved and how they lead to enhanced cholesterol transport and possibly to accelerated atherogenesis have not been fully clarified. Undoubtedly, the metabolic milieu in diabetes is complex and involves varying degrees of insulin deficiency and/or resistance and varying levels of plasma insulin, glucose, and fatty acids consistent with the heterogeneity of this disease. This heterogeneity is further complicated by the fact that lipoprotein metabolism in humans is also complex. Although kinetic studies have helped to delineate the major routes of plasma lipoprotein transport in humans and the overall defects in diabetes, the molecular mechanisms that govern lipoprotein synthesis, processing, and interactions are still unclear. Furthermore, the application of these technologies to the study of diabetes is still preliminary. Consequently, there is currently some uncertainty regarding the precise mechanisms by which diabetes could influence plasma lipoprotein metabolism. Therefore, the following account, based on current literature, should be interpreted with caution because this knowledge must be updated as understanding of these complex issues expands. VLDL. The etiology behind the increase in plasma VLDL levels has not been completely defined, although it has been suggested that the derangements in glucose, insulin, and free-fatty acid (FFA) metabolism present in diabetes are responsible. Hepatic VLDL-TG production is known to correlate closely with postprandial serum insulin levels in individuals with (31) and without (32) clinical diabetes. Plasma FFA levels are also strongly associated with increased hepatic VLDL-TG synthesis (33-38). The hypoinsulinemia present in IDDM, however, may impair the liver's ability to utilize plasma FFA to enhance VLDL synthesis to a comparable degree (32). This assumption receives support from studies employing perfused livers from streptozocin-induced diabetic rats, which demonstrate that increasing the FFA concentration of the perfusate results in increased VLDL-TG production only in those animals not rendered completely insulin deficient (39). Therefore, it appears that the elevation in VLDL concentrations in IDDM may not be due to increased hepatic VLDL production because sufficient insulin would not be present to play a permissive role in allowing increased VLDL-TG production in response to the increased plasma FFA. On the other hand, the absence of significant circulating insulin, as is often found in IDDM, may result in decreased VLDL clearance due to diminished activity of LPL, an enzyme that requires insulin for activation.
Increased VLDL-TG (29,36,40,41) and VLDL-apoB synthesis (42) have been demonstrated in NIDDM. Normolipemic mildly diabetic subjects (fasting glucose <150 mg/dl) with normal or increased circulating insulin levels have a concomitant increase in VLDL catabolic rate that maintains plasma VLDL concentrations at normal levels. However, hypoinsulinemic diabetic subjects with poorer glycemic control have a lower VLDL clearance rate in the presence of increased VLDL production and therefore become hypertriglyceridemic. Presumably, there may not have been enough insulin present to sufficiently activate LPL, although there may have been enough to allow enhanced hepatic VLDL production in response to increased plasma FFA and glucose concentrations (42).
Despite poor diabetic control and hyperinsulinism, Pima Indians have been reported to have normal hepatic VLDL-TG and apoB production, a finding explained by a lack of elevated FFA (43). In this population, elevated plasma VLDL was demonstrated to be due to a decrease in the VLDL catabolic rate. The reason for the unusual finding of normal FFA levels and normal VLDL production in Pima Indians remains unclear.
VLDL catabolism is largely mediated by LPL and therefore varies directly with the activity of this enzyme (41,44). Because LPL is activated by insulin (45), LPL activity is diminished in absolute insulin deficiency but may be normal in NIDDM patients with normal or increased levels of circulating insulin (40,41). In addition to decreased heparin-releasable plasma LPL, IDDM subjects with ketoacidosis demonstrate decreased LPL in adipose tissue and skeletal muscle (45). LPL levels in tissue and in postheparin plasma of insulin-deficient diabetic subjects show definite increases with insulin treatment and occasionally reach normal levels corresponding well to the increasing removal rate of VLDL-TG and the return of plasma TG to near normal levels (41,44,46). NIDDM subjects, on the other hand, do not show definite increases in LPL activity with insulin treatment (41). Therefore, it appears that deficient LPL activity is largely responsible for the hypertriglyceridemia seen in IDDM but may have a smaller or nonexistent role in the pathogenesis of the hypertriglyceridemia associated with NIDDM, which is associated more directly with increased VLDL production.
The metabolic fate of the increased VLDL transport in NIDDM is of great concern. In humans, VLDL particles are cleared from the circulation through two pathways. Complete delipidation of VLDL with conversion of the particle to LDL is the major route, but as much as 25% of VLDL is only partially delipidated, and the apoB in these molecules does not appear in LDL (47,48). These "remnant" VLDL particles are cleared by alternate routes, particularly by hepatic uptake via apoB-E receptors (49). For the normolipemic mildly diabetic subject with fasting glucose <150 mg/dl, VLDL-apoB synthesis and catabolism are increased, but the major catabolic pathway is via conversion to LDL, similar to that found in nondiabetic subjects (42). Because VLDLapoB production is greatly enhanced, the absolute amount of VLDL converted to LDL is also increased. In the hyperlipidemic mildly diabetic subject with more severe insulin resistance, the efficiency of VLDL to LDL conversion is decreased, and 40% of VLDL is catabolized as VLDL remnants without conversion to LDL. However, because the markedly elevated VLDL-apoB production overshadows the decreased rate of conversion to LDL, absolute LDL synthesis from VLDL remains elevated. Hyperlipidemic moderately severe diabetic subjects (fasting plasma glucose >150 mg/dl) continue to have the same elevated rate of VLDL-apoB production, but the fraction synthesized into LDL is reduced, and almost 60% of the VLDL is catabolized via the remnant pathway (42).
The etiology of the impaired efficiency of VLDL to LDL conversion in some diabetic subjects is unknown, but it is possible that VLDL subfractions in some diabetic subjects have an altered composition, which channels VLDL toward catabolism through the remnant pathway. In vitro studies indicate that large VLDL subfractions from hypertriglyceridemic patients are enriched with TG and cholesterol ester and are much less likely to result in LDL formation after lipolysis than smaller VLDL subfractions (50). Although compositional studies of whole VLDL in diabetic subjects have demonstrated similar TG, cholesterol, and apoB composition to nondiabetic subjects (42,51), it is possible that the VLDL subfractions vary considerably in composition from those found in nondiabetic subjects and, therefore, may have a strong influence on the metabolic fate of VLDL and, consequently, on LDL composition.
Although most remnant VLDL particles are effectively removed by the splanchnic region in normal subjects (52), in patients with insulin resistance or endogenous hypertriglyceridemia, the efficacy of hepatic extraction of remnant VLDL might be reduced, rendering a greater likelihood of metabolism by peripheral tissues (53,54). This is suggested by the demonstration of remnant VLDL uptake by rat aortic smooth muscle cells incubated in tissue culture (55). In addition, VLDL obtained from either normolipemic or hypertriglyceridemic NIDDM patients showed increased uptake by mouse peritoneal macrophages compared with VLDL from nondiabetic controls (56). This increased VLDL uptake, perhaps due to abnormal VLDL composition (14,57), may result in formation of lipid-laden foam cells and play an early role in the formation of atherosclerotic lesions.
Thus, it appears that most patients with NIDDM have a lipoprotein kinetic pattern characterized by increased VLDL turnover, often associated with hypertriglyceridemia when the VLDL catabolic pathways cannot keep pace with the increased production. With increasingly poor diabetic control, as manifested by hyperglycemia and hyperlipidemia, the efficiency of VLDL metabolism through the LDL pathway decreases, and reliance on alternative pathways increases. In the presence of insulin resistance, hepatic extraction of VLDL remnants may also become less efficient, resulting in more uptake by peripheral tissues. These abnormalities in VLDL metabolism may be one of the mechanisms for the predisposition toward coronary artery disease found in diabetes. LDL metabolism. Derangements in LDL metabolism have also been observed in NIDDM. Kinetic studies have indicated that LDL synthetic rates are markedly increased in normolipemic diabetic subjects with fasting plasma glucose <150 mg/dl (58). Hypertriglyceridemic diabetic subjects exhibiting the same degree of glycemia have lower LDL synthetic rates, which remain elevated when compared with weight-matched nondiabetic controls. In addition to the hypertriglyceridemia, fasting glucose elevations >150 mg/dl result in LDL synthetic rates that are not different from age-and weightmatched nondiabetic subjects. Because VLDL production rates were similarly elevated in each of the three groups, the decrease in LDL synthetic rates found with increasingly poor diabetic control probably reflects the deterioration of VLDL-to-LDL conversion efficiency described earlier. The LDL synthetic rate correlates directly with glucose-stimulated insulin levels in plasma (58), suggesting that insulin stimulation of LPL activity may result in more complete delipidation of VLDL and more efficient conversion to LDL. In obese nondiabetic subjects, adipose tissue LPL activity is directly related to postprandial insulin response (59). Because adipose tissue LPL and VLDL-apoB fractional clearance rate may be normal or even elevated in subjects with mild fasting hyperglycemia, it appears that less insulin may be necessary to stimulate LPL activity than is necessary to mediate glucose disposal.
The rate of LDL turnover is increased in normolipemic mildly diabetic subjects, resulting in normal plasma levels of LDL-chol (58). Therefore, an increase in LDL-chol transport, often associated with an increased likelihood of atherosclerosis, is expected despite the normal LDLchol concentration. The LDL catabolic rate is lowered in hyperlipidemic mildly diabetic subjects but remains elevated compared with nondiabetic subjects. In hyperlipemic diabetic subjects with fasting hyperglycemia, the LDL catabolic rate is reduced to below normal levels, resulting in elevations of LDL-chol. The LDL catabolic rate correlates directly with the glucose-stimulated insulin response, implying that insulin may interact with the LDL receptor to enhance LDL uptake and subsequent metabolism (58). Indeed, the addition of physiologic amounts of insulin to human skin fibroblasts in culture has been shown to enhance LDL binding to its receptor and stimulate receptor-mediated cell transport (60,61). In vivo studies have supported these findings (62). However, other factors present in diabetic sera may also be responsible for these changes (63).
Alterations in the compositions and/or density structure of the LDL particles might have an impact on the kinetic behavior of LDL in NIDDM. Furthermore, in vitro studies have demonstrated that hyperglycemia itself could result in nonenzymatic covalent binding of glucose to lysine residues in the LDL apoprotein (64). This process has also been demonstrated to occur in vivo (65) and to result in decreased LDL uptake in cultured human skin fibroblasts when as few as 6-15% of the LDL lysine residues are glycosylated (66) . Turnover studies employing labeled human glycosylated LDL in guinea pigs suggest that the LDL catabolic rate is decreased from 5 to 25% when only 2-5% of the LDL lysine residues are glycosylated (67). However, another report indicates that glycosylated LDL catabolism is abnormal only when the LDL apoB is heavily glycosylated, a situation unlikely to be found in nature (68) . Interestingly, examination of other apolipoproteins indicates that in addition to apoB, apolipoproteins Al, All, Cl, and E are also glycosylated in hyperglycemic subjects and, therefore, may play an important role in determining VLDL and HDL, as well as LDL metabolism (69) . The role that glycosylation of apoB plays in influencing VLDL and LDL kinetics in general and LDL receptormediated catabolism in particular will depend on the extent that this process occurs in the diabetic population and the elaboration of its effect on lipoprotein metabolism.
Aside from LDL glycosylation, LDL composition may be abnormal in other ways. LDL has been shown to be TG enriched in NIDDM and may be smaller in size (51,70). Elevations of plasma apoE levels have been found in poorly controlled NIDDM, which may correlate with a defect in reversed cholesterol transport, because in vitro cholesterol transport from cells to plasma improved when excess apoE was removed by immunoaffinity chromatography (71) . Increased ratios of free cholesterol to phospholipid have been demonstrated in VLDL and LDL obtained from NIDDM, an abnormality that appears to inhibit cholesterol ester transfer (72) . The significance of these compositional changes in LDL and their potential contribution to the increased incidence of atherosclerosis in diabetes is currently unknown and will require further elucidation.
In summary, increased VLDL-apoB production has been demonstrated in most subjects with NIDDM, an abnormality that results in increased LDL-apoB synthesis in diabetic subjects with a mild degree of hyperglycemia. Worsening of the glycemic state together with insulin deficiency is associated with the additive decrease in LDL catabolism. The increase in VLDL-TG synthesis and the aberration in VLDL-and LDL-apoB catabolism in NIDDM are closely allied with the prevailing metabolic milieu. The increase in apoB production, on the other hand, appears to be a fundamental feature of NIDDM and is not explained by the metabolic environment of the diabetic syndrome. HDL. HDL-chol levels in IDDM have been shown to be equivalent to (73) or higher than (73-78) those found in nondiabetic controls. ApoAl levels were also found to be slightly increased {77). No definite correlation between HDL-chol and glycemic control has been observed (78) .
There is considerable controversy regarding the effects of NIDDM on HDL composition and metabolism. One source of this confusion stems from the importance of employing nondiabetic control groups well matched for factors that significantly influence HDL metabolism, such as obesity, exercise pattern, sex, and smoking status (79) . Hypertriglyceridemia associated with poorly controlled diabetes may result in decreased HDL-chol independent of diabetes itself (80) . This inverse correlation between serum TG and cholesterol level is due to the close metabolic interaction between VLDL and HDL.
An additional source of variation in HDL-chol may be due to the choice of antidiabetic therapy. This may interact with both VLDL and HDL metabolism, resulting in different effects on HDL-chol concentration (74) . HDL-chol concentrations have been reported to be lower in type II diabetic patients receiving sulfonylurea therapy compared with patients receiving insulin in most (73, 75) but not all (81) studies. This depression with oral agents has been noted, particularly in the HDL 2 fraction, and it has been suggested, therefore, that insulin therapy may result in a more normal HDLchol to LDL-chol ratio (73) . Although normal values have been reported (76) , HDL-chol concentrations in NIDDM treated with diet alone appear to be depressed compared with those in nondiabetic controls (74, 81, 82) . Clarification of these results has been confounded by the use of nondiabetic controls not appropriately matched for the factors known to affect HDLchol levels, such as hypertriglyceridemia. Others, however, have noted decreased HDL-chol levels in dietcontrolled NIDDM patients matched for TG elevations as well as other variables (83) . Interestingly, apoAl has been found to remain similar to nondiabetic controls despite these decreases in HDL-chol and HDL 2 -chol values (82, 84) . Therefore, changes in HDL composition are likely to occur in NIDDM, resulting in a decreased cholesterol to apoAl ratio, suggesting a cholesterol-depleted HDL particle. In addition, HDL-TG may be increased (74, 76, 82) . The hypothesis has been suggested, therefore, that the number of HDL particles may remain unchanged, but the HDL-chol ester may be replaced by TG during the course of its transit through the circulation
(77).
Nikkila and Hormila (78) have suggested that HDL metabolism may be controlled by different factors in IDDM and NIDDM. IDDM patients receiving insulin demonstrate peripheral hyperinsulinemia, whereas hepatic insulinization remains deficient. This may result in decreased hepatic VLDL production, decreased hepatic lipase activity, and increased peripheral lipoprotein lipase activity. Because these insulin-sensitive lipases are probably involved in the catabolism and synthesis of HDL, they may play a role in producing the HDL ele-
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vations seen in NIDDM patients. Patients with NIDDM, on the other hand, have endogenous hyperinsulinemia but peripheral resistance to the action of insulin. This may have the reverse effect on the hepatic and Iipoprotein lipases and cause reductions in HDL-chol. The recently demonstrated inverse relationship between endogenous hyperinsulinemia (as measured by stimulated C-peptide levels) and HDL-chol concentrations in NIDDM supports this hypothesis (85) . Nevertheless, the precise mechanisms responsible for the decrease in plasma HDL concentration in NIDDM and its failure to improve with glycemic control, at least in some individuals, remain unclear.
WHAT IS EFFECT OF ANTID1ABETIC TREATMENT ON PLASMA LIP1DS AND LI POPROTEIN METABOLISM?
In IDDM, improved glycemic control by conventional insulin treatment reduces both plasma TG and VLDL concentrations to normal or near-normal levels (86) (87) (88) (89) . This reduction is accompanied by normalization of the VLDL transport kinetics (90) . Clycemic control further optimized by continuous subcutaneous insulin infusion usually does not result in lower VLDL concentration than that achieved by conventional multiple insulin injections (87) . In some individuals, however, intensive subcutaneous insulin infusion results in a more marked reduction in plasma VLDL, primarily due to a decrease in VLDL production below normal (90) .
Optimal glycemic control in IDDM also results in a significant reduction in plasma LDL concentration to normal or below-normal values (87) . Sustained reductions in LDL apoB and LDL-chol are often observed in individuals with poor initial diabetic control. Individuals with better glycemic control show no remarkable reduction in LDL concentration on the institution of intensive insulin therapy (86) . Thus, it appears that reductions in plasma LDL concentration can be achieved, but these reductions may be confined to those diabetic subjects who initially demonstrate a major impairment in glycemic control. A further reduction in LDL concentration to even below-normal levels could be achieved by intensified insulin therapy at the expense of inducing peripheral hyperinsulinemia (87, 88) .
Unlike the rapid normalization of VLDL and LDL concentrations with optimal insulin therapy in IDDM, changes in HDL concentration may be more gradual. No increase in HDL-chol was observed after 3 wk of insulin therapy (87), but a rise was noted with a longer treatment (91) . Indeed, significant increases in both HDL-chol and HDL-apoAl levels have been observed after optimization of glycemic control by either conventional techniques or by continuous subcutaneous insulin infusion (86) . Thus, optimal insulin treatment of IDDM patients appears to correct the abnormalities in plasma lipoprotein concentrations and exert a favorable influence on the HDL-chol to LDL-chol ratio.
Evaluating the effect of antidiabetic therapy on lipoprotein metabolism in NIDDM is complicated by the fact that treatment can consist of diet, oral agents, and insulin. The type of therapy may thus affect plasma lipoprotein concentration and composition independent of its ability to improve glycemic control. For this reason, results of therapy appear to be heterogenous in NIDDM compared to IDDM.
When obese NIDDM patients are treated with diet alone, changes in plasma lipoprotein concentration are dependent on the degree of weight loss. A decrease in plasma TG of 20% associated with a 5% weight loss and a 20% reduction in blood glucose after 1 mo of dietary treatment is reported. At 1 yr, however, plasma TG returned to pretreatment levels, despite persistent improvement in weight and serum glucose concentrations (92) . On the other hand, when a weight reduction of 10% is maintained, a sustained improvement in plasma TG, HDL-chol, and HDL-chol to total cholesterol ratio is observed (93) . Diabetic patients hospitalized and placed on hypocaloric diets demonstrate even more marked improvement in plasma lipoprotein concentrations. Pima Indians who averaged 6 kg/mo weight loss for up to 8 mo demonstrated marked reductions in plasma VLDL-TG, particularly in those who were initially hypertriglyceridemic. Although HDL-chol was unchanged during weight loss in this population, a persistent 20% decrease in LDL-chol was noted, resulting in an improved HDL-chol to LDL-chol ratio (94) . In another study, both the immediate and long-term effects of supplemental fasting (200 kcal/day for 3 wk) were evaluated in obese NIDDM. Most patients were initially hypertriglyceridemic and showed a 47% reduction in plasma TG concentration, which persisted after 4 mo of follow-up. Serum cholesterol and apoB levels showed an initial reduction but returned to baseline values by 4 mo. Marked reductions in body weight and plasma glucose were obtained and persisted throughout the course of the study (95) . Decreases in VLDL-TG were due to decreased synthesis in most patients because the VLDL removal rate and LPL activity were unchanged during a hypocaloric diet (95, 96) . In most studies, HDL-chol is usually increased in NIDDM when weight loss has been achieved (93, (96) (97) (98) , although some investigators have reported no change (94) . Treatment of NIDDM with sulfonylurea results in improved glycemic control and reduced TG concentrations (99) (100) (101) (102) . Small but significant increases in HDL-chol have been observed (99) ; however, most studies report no definite change in HDL-chol (100-102) or plasma apoAl (102) levels. In fact, HDL-chol was reported to be decreased with sulfonylurea therapy in one study (103) . No increase in VLDL-TG removal was found, suggesting that the reduction in VLDL was related to decreased synthesis (99) .
Significant decreases in plasma TG have also been noted when glycemic control in NIDDM is optimized with insulin. Reductions of up to 100% in plasma TG concentration have been observed, particularly when patients are hypertriglyceridemic before insulin therapy DIABETES CARE, VOL. 1 1 , N O . 2, FEBRUARY 1988 (29). These reductions are associated with decreases in VLDL-TG production, but increases in LPL activity and TG clearance have also been found (99, 104) . Reductions in LDL-chol have been noted in most (99, 105) , but not all (29), studies in which insulin therapy is used to improve diabetic control. Small but significant increases in HDL-chol are observed in most (99, 29, 105) but not all (106) studies in which glycemic control is improved with insulin.
In summary, improved glycemic control obtained through diet, oral agents, or insulin therapy results in substantial improvement of plasma lipids and lipoprotein concentrations. The extent of these changes correlates with the degree of improvement in glycemia and appears to be greatest in those individuals treated with insulin. However, as is true for IDDM, abnormalities in lipoprotein composition are not necessarily corrected with improved glycemic control (57,90), and therefore it is possible that LDL and VLDL particles may retain an increased propensity for atherogenesis despite the reduction in their concentrations. Although VLDL-TG synthesis is often reduced with treatment, further evaluation of apoB metabolism is necessary to assess the potential for improved glycemic control to reduce apoB synthesis. Optimum treatment of hyperglycemia is often accompanied by some improvement in plasma HDL levels, particularly when associated conditions such as obesity are dealt with at the same time.
WHAT EVIDENCE IS THERE THAT MODIFIED-FAT DIET COULD EXERT FAVORABLE BENEFITS OVER AND ABOVE WHAT COULD BE ACHIEVED BY OPTIMAL ANTIDIABETIC THERAPY?
The association of a high intake of saturated fat and cholesterol with increased plasma lipid levels and coronary heart disease is well established. Therefore, there are concerns about the appropriate diet that will have the most favorable effect on plasma lipoprotein metabolism in diabetes. Many factors exert important effects, including the proportion and composition of dietary fat and cholesterol.
Based on studies in experimental animals and a wide range of epidemiological surveys and dietary intervention trials, the AHA Nutrition Committee developed the rationale for recommending that the American public reduce its daily fat intake to 30% of total calories, saturated fat to <10%, polyunsaturated fat to 10%, with the remaining calories consisting of monosaturated fat, and that cholesterol should not exceed 300 mg/day (AHA phase I diet). The rationale and documentation of the particular recommendations for this diet are described elsewhere (107) .
In the majority of diabetic subjects, particularly those with optimal glycemic control, plasma cholesterol and TG concentrations are not elevated. Because of the high risk of CVD in diabetes, and because of the favorable effects of the AHA recommended diet on plasma lipids and CVD in the nondiabetic population, it is recommended that this diet be prescribed as part of the dietary management of all diabetic patients. This recommendation, however, should be considered as a minimum requirement because the abnormality in plasma VLDL and LDL transport, particularly with respect to the increased apoB transport, is still observed in individuals with normal plasma lipid levels.
Because reducing caloric intake from fat to a maximum of 30% would require an increase in carbohydrates, the effect of this dietary modification on plasma lipids and lipoproteins is reviewed. The potential effect of some types of dietary fiber intake and special fatty acid supplements (omega-3 fatty acid) and weight control are also addressed in many studies.
Initial studies evaluating the use of fat-restricted highcarbohydrate diets raised the concern that they may induce elevations of plasma TG concentration in both normal (108, 109) and hypertriglyceridemic (110) individuals. Elevated VLDL-TG synthesis without an increase in VLDL-apoB production has been demonstrated with a high-carbohydrate diet (111) , resulting in VLDL particles that have an increased TG to apoB ratio in most subjects (111, 112) . In these individuals, however, a decrease in VLDL conversion to LDL has been noted, suggesting a compensatory increase in VLDL catabolism by alternate pathways, presumably by increased hepatic uptake of remnant VLDL particles (113) . In addition, mild reductions are observed in both LDL-chol and HDL 2 -chol (109, 111, 112) . Both apoB and apoAl are decreased shortly after a high-carbohydrate diet is instituted (114) . Our preliminary data show a reduction in VLDL-apoB conversion to LDL and a decrease in LDL synthesis in mild NIDDM patients given a high-carbohydrate diet (unpublished results). The long-term effects of this diet on the metabolic fate of VLDL and LDL particles and how the atherogenic mechanisms could be influenced in diabetes remain to be established.
The mechanisms underlying the hypocholesterolemic effect of certain kinds of dietary fiber are unknown. Diets enriched with wheat bran and guar gum induce 10-20% reductions in serum cholesterol in both normal (115) and hypercholesterolemic (116) subjects. When added in large quantities to a high-carbohydrate diet, fiber may have the ability to blunt the hypertriglyceridemic response induced by a high-carbohydrate lowfiber diet in NIDDM patients (117) . Furthermore, a significant reduction in LDL-chol is noted without hypertriglyceridemia when a high-carbohydrate high-fiber diet is given to IDDM and NIDDM patients. These improvements are not observed with a high-carbohydrate diet alone (118) . However, not all NIDDM patients are benefited by the addition of dietary fiber (119) , and a fat-restricted high-carbohydrate diet even without the fiber supplementation may improve glycemic control without deleterious changes in lipid levels (120) .
In most outpatient studies evaluating self-selected high-carbohydrate diets, 50-60% of the diet consists of carbohydrate and -3 0 % consists of fat. The fatty acid composition and cholesterol content of the fat portion of the diet have well-recognized effects on lipoprotein metabolism. The addition of cholesterol to the diet causes increases in total cholesterol and LDL-chol (121) , an effect that depends on the low polyunsaturated to saturated (P/S) fat ratio in the diet (122) . Cholesterolrestricted diets, on the other hand, can produce a 20% decrease in plasma cholesterol in normal and hypercholesterolemic subjects (123) .
Increases in polyunsaturated fatty acids to maintain a dietary P/S ratio of ^0.8 have pronounced hypocholesterolemic effects (124) . Reductions in LDL-chol and LDL apoB of 10-20% are achieved consistently with diets high in polyunsaturated fat, due to increased LDL clearance in some subjects (125) and decreased LDL synthesis in others (126) . Both VLDL-chol and HDL-chol concentrations are generally reduced with high P/S ratio diets (125) , and thus, only moderate improvements in the HDL-chol to LDL-chol ratio may result. Plasma levels of apoAl, apoB, and HDL 2 -chol declined in both normocholesterolemic (127) and hypercholesterolemic (128) subjects placed on >2.0 P/S ratio diets for short periods. However, other dietary trials that use diets with a more moderate P/S ratio of 1.0 reveal no decrease in apoAl or HDL levels and therefore achieved significant improvements in the HDL-chol to LDL-chol ratio (129, 130) .
Favorable effects on lipoprotein metabolism may not be limited to fatty acids that are polyunsaturated. Dietary trials comparing monounsaturated fatty acids with polyunsaturated fatty acids demonstrate comparable reductions in LDL but less of an HDL-lowering effect for the monounsaturated oil (131) . The ability of monounsaturated oil to selectively lower LDL-chol but not HDLchol is confirmed in individuals with moderate hypercholesterolemia (132) . Although further evaluation of the lipid-lowering effect of monounsaturated fatty acids in diabetic subjects is warranted, it appears that these fatty acids may have effects on HDL and LDL concentrations equally favorable to those of polyunsaturated fatty acids. Perhaps because of their increased susceptibility to oxidation, polyunsaturated fatty acids have been found to promote carcinogenesis in experimental animals (133) . For this reason, it is recommended that the percentage of polyunsaturated fat be confined to 6-8%.
Recently, it has been recognized that certain essential fatty acids of the omega-3 class, found in fish oils, particularly eicosapentaenoic acid and docosahexaenoic acid, may potentially reduce the CVD risk in diabetes. Their effects include 7) reducing plasma VLDL-TG concentrations in both normolipemic and hypertriglyceridemic subjects by decreasing VLDL production (134-136), 2) lowering blood pressure (137) , and 3) prolonging platelet aggregation and bleeding time by depressing thromboxane A 2 formation (138, 139) . Because diabetes is often associated with increases in VLDL production, elevated blood pressure, and platelet hyperaggregability with increased thromboxane A 2 formation (140), dietary fish-oil supplementation would appear to have the potential to favorably influence these risk factors. Although preliminary reports indicate improved platelet function in IDDM when supplemented with small amounts of fish oil (141), there remains a paucity of data concerning the effect of fish-oil supplementation on the abnormal lipoprotein metabolism and composition found in diabetes.
The presence of obesity in NIDDM may have an independent deleterious effect on lipoprotein metabolism. Nondiabetic individuals who are overweight demonstrate increased VLDL production that may result in hypertriglyceridemia (142,143). Increased synthesis of LDL is also observed, although LDL concentration is normal in most patients due to a concomitant increase in LDL clearance (142,144). Weight reduction is associated with a decrease in VLDL and LDL production (143). Although initial decreases with weight loss are often observed (145,146), HDL-chol may increase to baseline rates or above when the weight reduction is maintained (146,147). In NIDDM, correcting the overweight also improves glycemic control, which has a further beneficial effect on lipoprotein metabolism (94, 95) .
Because plasma cholesterol concentration in some diabetic individuals may be increased even after optimal glycemic control is obtained, and because the risk for CVD in these patients is increased, an even more fatrestricted diet comparable to the AHA phase II (fat 25% of cal, cholesterol 200-250 mg/day) or phase III (fat 20% of cal, cholesterol 100-150 mg/day) diet, with or without appropriate hypolipemic drugs, should be prescribed. The rationale for this action and the specifics of this recommendation are detailed in the Joint Statement of the Nutrition Committee and Council on Arteriosclerosis of the AHA (148).
In the unusual circumstance in which extreme hypertriglyceridemia develops (1000-2000 mg/dl, chylomicronemia syndrome), a fat-restricted diet (<20% of total cal) together with appropriate antidiabetic therapy (insulin or sulfonylurea) and possibly a hypotriglyceridemic agent such as a fibric acid derivative are indicated to avoid pancreatitis. Alcohol, which stimulates synthesis of TG, should be avoided, and obesity, which has the same effect, should be managed. However, because rapid weight loss increases the risk for pancreatitis, gradual weight reduction is preferred. Estrogens and glucocorticoids exert exacerbating effects and should also be avoided.
To summarize, a modified-fat diet has a salutary effect on lipid and lipoprotein levels in diabetes. Although diets rich in carbohydrate may enhance VLDL-TG synthesis, VLDL-apoB production is not increased, and the altered VLDL structure may result in enhanced hepatic uptake of remnant VLDL particles and reduction in LDL synthesis. The presence of large amounts of certain dietary fiber may act to blunt this hypertriglyceridemic response and in addition, has a separate hypocholesterolemic effect. Although diets containing a P/S ratio >0.8 reliably reduce LDL concentrations compared with a conventional American diet, HDL levels may also be lowered, and the safety of consuming such diets over long periods has not been determined. Monounsaturated fatty acids, on the other hand, do not appear to have an adverse effect on HDL levels and therefore should also be included in the diet. Correction of obesity has a beneficial effect on lipoprotein levels, because VLDL and LDL levels are reduced due to a decrease in the synthetic rate of these particles. Therefore, the available literature suggests that adoption of the dietary guidelines outlined in this article can be expected to have a favorable influence on lipid and lipoprotein levels, as well as on cardiovascular risk. 
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